The results and conclusions of the work conducted by the Lymphoma Research Experts ecosystem are published in leading medical journals.
Lysa 2020_LYSA_Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group
Lysa 2020_LYSA_Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T 3 phase IB trial of the LYSA
Lysa 2020_LYSA_Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study
Lysa 2020_LYSA_Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network
Lysa 2020_LYSA_Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group
Lysa 2020_LYSA_Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
Lysa 2020_LYSA_Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA
Lysa 2020_LYSA_Risk stratification in diffuse large B cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT
Lysa 2020_LYSA_Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
Calym 2017_RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma.
Calym 2019_Overexpression of Claspin and Timeless protects cancer cells from replication stress in a checkpoint-independent manner.
Calym 2017_Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell.